Johan Dighed - Karolinska Development Chief CEO
| KDEV Stock | SEK 1.08 0.01 0.93% |
Insider
Johan Dighed is Chief CEO of Karolinska Development AB
| Age | 50 |
| Phone | 46 8 52 48 60 70 |
| Web | https://www.karolinskadevelopment.com |
Karolinska Development Management Efficiency
The company has return on total asset (ROA) of (0.0168) % which means that it has lost $0.0168 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.1059) %, meaning that it generated substantial loss on money invested by shareholders. Karolinska Development's management efficiency ratios could be used to measure how well Karolinska Development manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Bjrn Frendus | BioInvent International AB | 50 | |
| Pr Lannfelt | BioArctic AB | 74 | |
| Marcuss | Cantargia AB | N/A | |
| Adnan Deronic | Cantargia AB | N/A | |
| MSc MD | Oncopeptides AB | N/A | |
| Ingrid Teige | BioInvent International AB | N/A | |
| Katja Margell | Hansa Biopharma AB | N/A | |
| Peter Nygren | Oncopeptides AB | 64 | |
| Dominique Tersago | Cantargia AB | 61 | |
| MSc MSc | Oncopeptides AB | 53 | |
| Frida Lekander | BioArctic AB | N/A | |
| Jan Mattsson | BioArctic AB | 63 | |
| Pr Gellerfors | BioArctic AB | 76 | |
| Klaus Sindahl | Hansa Biopharma AB | N/A | |
| Nina Valkama | Cantargia AB | N/A | |
| Jakob Lic | Oncopeptides AB | 51 | |
| Gunilla Andersson | BioArctic AB | 62 | |
| Christer Mller | BioArctic AB | 64 | |
| RGN MSc | BioInvent International AB | N/A | |
| Ignacio GarciaRibas | Cantargia AB | N/A | |
| Linda Holmstrom | Oncopeptides AB | N/A | |
Management Performance
| Return On Equity | -0.11 | |||
| Return On Asset | -0.0168 |
Karolinska Development Leadership Team
Elected by the shareholders, the Karolinska Development's board of directors comprises two types of representatives: Karolinska Development inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Karolinska. The board's role is to monitor Karolinska Development's management team and ensure that shareholders' interests are well served. Karolinska Development's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Karolinska Development's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Per Aniansson, Investment Director | ||
| Eva Montgomerie, Head of Accounting | ||
| Johan Dighed, Chief CEO | ||
| Linda Spahiu, Investment Mang | ||
| Yan Cheng, President Asia | ||
| Hans Toll, Chief Officer | ||
| Viktor MD, Chief Officer | ||
| John MD, Chief Partner |
Karolinska Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Karolinska Development a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.11 | |||
| Return On Asset | -0.0168 | |||
| Operating Margin | (14.44) % | |||
| Current Valuation | 247.24 M | |||
| Shares Outstanding | 267.28 M | |||
| Shares Owned By Insiders | 37.17 % | |||
| Shares Owned By Institutions | 5.97 % | |||
| Price To Earning | 7.42 X | |||
| Price To Book | 0.37 X | |||
| Price To Sales | 204.26 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Karolinska Stock Analysis
When running Karolinska Development's price analysis, check to measure Karolinska Development's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Karolinska Development is operating at the current time. Most of Karolinska Development's value examination focuses on studying past and present price action to predict the probability of Karolinska Development's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Karolinska Development's price. Additionally, you may evaluate how the addition of Karolinska Development to your portfolios can decrease your overall portfolio volatility.